Antonio Maria Chiarelli1, Daniele Mascali1, Nikolaos Petsas2, Carlo Pozzilli2, Richard Geoffrey Wise1, and Valentina Tomassini1
1Department of Neuroscience, Imaging and Clinical Sciences, University G. D'Annunzio of Chieti Pescara, Chieti Scalo, Italy, 2Department of Neurology and Psychiatry, Sapienza University, Rome, Italy
1Department of Neuroscience, Imaging and Clinical Sciences, University G. D'Annunzio of Chieti Pescara, Chieti Scalo, Italy, 2Department of Neurology and Psychiatry, Sapienza University, Rome, Italy
BOLD-CVR in MS increased,
and the identified association with GM volume was lost, with immunomodulatory therapy.
Cerebrovascular alteration in MS is modifiable
by immunomodulation. If persistent, it may
contribute to neurodegeneration.
Figure 3: Maps of change in CVR with immunomodulation
in MS patients: (a) map in absolute units; (b) Statistical Parametric (t-score)
map; (c) thresholded (p<0.05) map of null-hypothesis probability, corrected
for multiple comparison using the threshold free cluster enhancement (TFCE)
approach. Coordinates (in mm) refers to the MNI152 template.
Figure 2: (a) Global CVRs in GM;
Left: Average and associated standard error of the mean; Right: Violin plots. (b) Change in CVR with treatment as
a function of the pre-treatment CVR in GM. (** p<0.01)
